Biomarkers predicting antidepressant treatment response: How can we advance the field?

Disease Markers

Volumn 35, Issue 1, 2013, Pages 23-31

  Labermaier, Christiana ^a   Masana, Mercè ^a   Müller, Marianne B ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; DNA; MICRORNA; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

CLINICAL TRIAL; ENVIRONMENTAL FACTOR; EPIGENETICS; EVIDENCE BASED PRACTICE; GENOMICS; HUMAN; MAJOR DEPRESSION; MEDICAL DECISION MAKING; NEUROIMAGING; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; EPIGENESIS, GENETIC; GENE-ENVIRONMENT INTERACTION; HUMANS; METABOLOME; MICRORNAS; PROTEOME; TRANSCRIPTOME; TREATMENT OUTCOME;

EID: 84883115048     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/984845     Document Type: Review

References (68)

1. C. J. Murray, T. Vos, R. Lozano et al., "Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden for disease study," The Lancet, vol. 380, no. 9859, pp. 2197-2223, 2012.
2. J. Olesen, A. Gustavsson, M. Svensson, H. U. Wittchen, and B. Jönsson, "The economic cost for brain disorders in Europe," European Journal for Neurology, vol. 19, no. 1, pp. 155-162, 2012.
3. *D: implications for clinical practice," The American Journal for Psychiatry, vol. 163, no. 1, pp. 28-40, 2006.
4. A. F. Leuchter, I. A. Cook, S. P. Hamilton et al., "Biomarkers to predict antidepressant response," Current Psychiatry Reports, vol. 12, no. 6, pp. 553-562, 2010.
5. G. I. Papakostas, "Surrogate markers for treatment outcome in major depressive disorder," International Journal for Neuropsy-chopharmacology, vol. 15, no. 6, pp. 841-854, 2012.
6. F. Holsboer, "How can we realize the promise for personalized antidepressant medicines?" Nature Reviews Neuroscience, vol. 9, no. 8, pp. 638-646, 2008.
7. A. H. Kemp, E. Gordon, A. J. Rush, and L. M. Williams, "Improving the prediction for treatment response in depression: integration for clinical, cognitive, psychophysiological, neuroimaging, and genetic measures," CNS Spectrums, vol. 13, no. 12, pp. 1066-1086, 2008.
8. A. J. Rush, S. R. Wisniewski, D. Warden et al., "Selecting among second-step antidepressant medication monotherapies: predictive value for clinical, demographic, or first-step treatment features," Archives for General Psychiatry, vol. 65, no. 8, pp. 870-880, 2008.
9. M. Adli, A. J. Rush, H. J. Möller, and M. Bauer, "Algorithms for optimizing the treatment for depression: making the right decision at the right time," Pharmacopsychiatry, vol. 36, supplement 3, pp. S222-S229, 2003.
10. L. P. Hölzel, L. Kriston, A. K. Weiser, and M. Härter, "Cross-national differences in inpatient depression treatment," European Psychiatric Review, vol. 4, pp. 32-34, 2011.
11. M. N. Pangalos, L. E. Schechter, and O. Hurko, "Drug development for CNS disorders: strategies for balancing risk and reducing attrition," Nature Reviews Drug Discovery, vol. 6, no. 7, pp. 521-532, 2007.
12. Y. Agid, G. Buzsáki, D. M. Diamond et al., "How can drug discovery for psychiatric disorders be improved?" Nature Reviews Drug Discovery, vol. 6, no. 3, pp. 189-201, 2007.
13. J. A. Wagner, "Overview for biomarkers and surrogate endpoints in drug development," Disease Markers, vol. 18, no. 2, pp. 41-46, 2002.
14. H. C. Kraemer, G. T. Wilson, C. G. Fairburn, and W. S. Agras, "Mediators and moderators for treatment effects in randomized clinical trials," Archives for General Psychiatry, vol. 59, no. 10, pp. 877-883, 2002.
15. K. S. Kendler and M. C. Neale, "Endophenotype: a conceptual analysis," Molecular Psychiatry, vol. 15, no. 8, pp. 789-797, 2010.
16. G. E. Simon and R. H. Perlis, "Personalized medicine for depression: can we match patients with treatments?" The American Journal for Psychiatry, vol. 167, no. 12, pp. 1445-1455, 2010.
17. D. Slamon, W. Eiermann, N. Robert et al., "Adjuvant trastuzumab in HER2-positive breast cancer," The New England journal for medicine, vol. 365, no. 14, pp. 1273-1283, 2011.
18. F. Holsboer, "The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety," Journal for Psychiatric Research, vol. 33, no. 3, pp. 181-214, 1999.
19. F. Holsboer, "The corticosteroid receptor hypothesis for depression," Neuropsychopharmacology, vol. 23, no. 5, pp. 477-501, 2000.
20. E. R. de Kloet, E. Vreugdenhil, M. S. Oitzl, and M. Jöels, "Brain corticosteroid receptor balance in health and disease," Endocrine Reviews, vol. 19, no. 3, pp. 269-301, 1998.
21. F. C. Raadsheer, W. J. G. Hoogendijk, F. C. Stam, F. J. H. Tilders, and D. F. Swaab, "Increased numbers for corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus for depressed patients," Neuroendocrinology, vol. 60, no. 4, pp. 436-444, 1994.
22. J. S. Purba, W. J. G. Hoogendijk, M. A. Hofman, and D. F. Swaab, "Increased number for vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus for the hypothalamus in depression," Archives for General Psychiatry, vol. 53, no. 2, pp. 137-143, 1996.
23. M. B. Müller, R. Landgraf, J. Preil et al., "Selective activation for the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids," Endocrinology, vol. 141, no. 11, pp. 4262-4269, 2000.
24. F. Holsboer and N. Barden, "Antidepressants and hypothalamicpituitary-adrenocortical regulation," Endocrine Reviews, vol. 17, no. 2, pp. 187-205, 1996.
25. I. Heuser, A. Yassouridis, and F. Holsboer, "The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders," Journal for Psychiatric Research, vol. 28, no. 4, pp. 341-356, 1994.
26. F. Holsboer, A. Gerken, G. K. Stalla, and O. A. Müller, "Blunted aldosterone and ACTH release after human CRH administration in depressed patients," The American Journal for Psychiatry, vol. 144, no. 2, pp. 229-231, 1987.
27. A. W. Zobel, A. Yassouridis, R. Frieboes, and F. Holsboer, "Prediction for medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression," The American Journal for Psychiatry, vol. 156, no. 6, pp. 949-951, 1999.
28. M. Ising, S. Horstmann, S. Kloiber et al., "Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker?" Biological Psychiatry, vol. 62, no. 1, pp. 47-54, 2007.
29. H. S. Mayberg, S. K. Brannan, J. L. Tekell et al., "Regional metabolic effects for fluoxetine in major depression: serial changes and relationship to clinical response," Biological Psychiatry, vol. 48, no. 8, pp. 830-843, 2000.
30. S. H. Kennedy, K. R. Evans, S. Krüger et al., "Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment for major depression," The American Journal for Psychiatry, vol. 158, no. 6, pp. 899-905, 2001.
31. S. H. Kennedy, J. Z. Konarski, Z. V. Segal et al., "Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial," The American Journal for Psychiatry, vol. 164, no. 5, pp. 778-788, 2007.
32. H. S. Mayberg, "Modulating limbic-cortical circuits in depression: targets for antidepressant treatments," Seminars in Clinical Neuropsychiatry, vol. 7, no. 4, pp. 255-268, 2002.
33. G. Siegle, G. J, W. K. Thompson et al., "Toward clinically useful neuroimaging in depression treatment: prognostic utility for subgenual cingulate activity for determining depression outcome in cognitive therapy across studies, scanners, and patient characteristics," Archives for General Psychiatry, vol. 69, no. 9, pp. 913-924, 2012.
34. J. de Leon, "Pharmacogenomics: the promise for personalized medicine for CNS disorders," Neuropsychopharmacology, vol. 34, no. 1, pp. 159-172, 2009.
35. L. Franchini, A. Serretti, M. Gasperini, and E. Smeraldi, "Familial concordance for fluvoxamine response as a tool for differentiating mood disorder pedigrees," Journal for Psychiatric Research, vol. 32, no. 5, pp. 255-259, 1998.
36. J. Kirchheiner, A. Seeringer, and R. Viviani, "Pharmacogenetics in psychiatry - a useful clinical tool or wishful thinking for the future?" Current Pharmaceutical Design, vol. 16, no. 2, pp. 136-144, 2010.
37. S. Porcelli, C. Fabbri, and A. Serretti, "Meta-analysis for serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy," European Neuropsychopharmacology, vol. 22, no. 4, pp. 239-258, 2012.
38. E. B. Binder, D. Salyakina, P. Lichtner et al., "Polymorphisms in FKBP5 are associated with increased recurrence for depressive episodes and rapid response to antidepressant treatment," Nature Genetics, vol. 36, no. 12, pp. 1319-1325, 2004.
39. K. A. Ellsworth, I. Moon, B. W. Eckloff et al., "FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder," Pharmacogenetics and Genomics, vol. 23, no. 3, pp. 156-166, 2013.
40. *D) cohort," Biological Psychiatry, vol. 63, no. 12, pp. 1103-1110, 2008.
41. M. Uhr, M. T. Grauer, and F. Holsboer, "Differential enhancement for antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption," Biological Psychiatry, vol. 54, no. 8, pp. 840-846, 2003.
42. M. Uhr, T. Steckler, A. Yassouridis, and F. Holsboer, "Penetration for amitriptyline, but not for fluoxetine, into brain is enhanced in mice with blood-brain barrier defficiency due to Mdr1a P-glycoprotein gene disruption," Neuropsychopharmacology, vol. 22, no. 4, pp. 380-387, 2000.
43. M. Uhr, A. Tontsch, C. Namendorf et al., "Polymorphisms in the drug transporter gene ABCB1 Predict antidepressant treatment response in depression," Neuron, vol. 57, no. 2, pp. 203-209, 2008.
44. R. Keers and K. J. Aitchison, "Pharmacogenetics for antidepressant response," Expert Review for Neurotherapeutics, vol. 11, no. 1, pp. 101-125, 2011.
45. M. Ising, S. Lucae, E. B. Binder et al., "A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression," Archives for General Psychiatry, vol. 66, no. 9, pp. 966-975, 2009.
46. GENDEP Investigators, MARS Investigators, and STARD Investigators, "Common genetic variation and antidepressant efficacy in major depressive disorders: a meta-analysis for three genome-wide pharmacogenetic studies," The American Journal for Psychiatry, vol. 170, no. 2, pp. 207-217, 2013.
47. J. W. Smoller, N. Craddock, K. Kendler et al., "Identification for risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis," The Lancet, vol. 381, no. 9875, pp. 1371-1379, 2013.
48. A. Serretti and C. Fabbri, "Shared genetics among major psychiatric disorders," The Lancet, vol. 381, no. 9875, pp. 1339-1341, 2013.
49. D. M. de Souza, L. W. Harris, P. C. Guest, C. W. Turck, and S. Bahn, "The role for proteomics in depression research," European Archives for Psychiatry and Clinical Neuroscience, vol. 260, no. 6, pp. 499-506, 2010.
50. D. M. de Souza, "Comprehending depression through proteomics," International Journal for Neuropsychopharmacology, vol. 15, no. 10, pp. 1373-1374, 2012.
51. F. Mamdani, M. T. Berlim, M.-. Beaulieu, A. Labbe, C. Merette, and G. Turecki, "Gene expression biomarkers for response to citalopram treatment in major depressive disorder," Translational Psychiatry, vol. 1, article e13, 2011.
52. C. Webhofer, P. Gormanns, S. Reckow et al., "Proteomic and metabolomic profiling reveals time-dependent changes in hippocampal metabolism upon paroxetine treatment and biomarker candidates," Journal for Psychiatric Research, vol. 47, no. 3, pp. 289-298, 2013.
53. K. Malki, J. Campbell, M. Davies et al., "Pharmacoproteomic investigation into antidepressant responsein two inbred mouse strains," Proteomics, vol. 12, no. 14, pp. 2355-2365, 2012.
54. R. Kaddurah-Daouk, S. H. Boyle, W. Matson et al., "Pretreatment metabotype as a predictor for response to sertraline or placebo in depressed outpatients: a proof for concept," Translational Psychiatry, vol. 1, article e26, 2011.
55. L. He and G. J. Hannon, "MicroRNAs: small RNAs with a big role in gene regulation," Nature Reviews Genetics, vol. 5, no. 7, pp. 522-531, 2004.
56. S. Mouillet-Richard, A. Baudry, J. Launay, and O. Kellermann, "MicroRNAs and depression," Neurobiology for Disease, vol. 46, no. 2, pp. 272-278, 2012.
57. K. Oved, A. Morag, M. Pasmanik-Chor et al., "Genome-wide miRNA expression profiling for human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers," Pharmacogenomics, vol. 13, no. 10, pp. 1129-1139, 2012.
58. R. M. O'Connor, T. G. Dinan, and J. F. Cryan, "Little things on which happiness depends: MicroRNAs as novel therapeutic targets for the treatment for anxiety and depression," Molecular Psychiatry, vol. 17, no. 4, pp. 359-376, 2012.
59. J. Juhila, T. Sipilä, K. Icay et al., "MicroRNA expression profiling reveals MiRNA families regulating specific biological pathways in mouse frontal cortex and hippocampus," PLoS ONE, vol. 6, no. 6, Article ID e21495, 2011.
60. N. Tsankova, W. Renthal, A. Kumar, and E. J. Nestler, "Epigenetic regulation in psychiatric disorders," Nature Reviews Neuroscience, vol. 8, no. 5, pp. 355-367, 2007.
61. V. Vialou, J. Feng, A. J. Robinson, and E. J. Nestler, "Epigenetic mechanisms for depression and antidepressant action," Annual Review for Pharmacology and Toxicology, vol. 53, pp. 59-87, 2013.
62. H. Sun, P. J. Kennedy, and E. J. Nestler, "Epigenetics for the depressed brain: role for histone acetylation and methylation," Neuropsychopharmacology, vol. 38, no. 1, pp. 124-137, 2013.
63. M. Kurita, T. Holloway, A. Garzia-Bea et al., "HDAC2 regulates atypical antipsychotic responses through the modulation for mGlu2 promotor activity," Nature Neuroscience, vol. 15, no. 9, pp. 1245-1254, 2012.
64. K. Malki, R. Uher, J. Paya-Cano et al., "Convergent animal and human evidence suggests a role for PPM1A gene in response to antidepressants," Biological Psychiatry, vol. 69, no. 4, pp. 360-365, 2011.
65. O. Berton, C. G. Hahn, and M. E. Thase, "Are we getting closer to valid translational models for major depression?" Science, vol. 338, no. 6103, pp. 75-79, 2012.
66. B. W. Dunlop, E. B. Binder, J. F. Cubells et al., "Predictors for remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial," Trials, vol. 13, article 106, 2012.
67. K. Ganea, A. Menke, M. V. Schmidt et al., "Convergent animal and human evidence suggests the activin/inhibin pathway to be involved in antidepressant response," Translational Psychiatry, vol. 2, article e177, 2012.
68. M. A. Kohli, S. Lucae, P. G. Saemann et al., "The neuronal transporter gene SLC6A15 confers risk to major depression," Neuron, vol. 70, no. 2, pp. 252-265, 2011.